StockData
Black Diamond Therapeutics, Inc. logo

Black Diamond Therapeutics, Inc. (BDTX) stock

BDTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/30
$1.47−0.05 (-3.29%)

Close on Nov 13, 2026Market cap $84.46MP/E –Yield –

Earnings

Black Diamond Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 15, 2027
Q4 FY2026 · estimated, during market hours
Revenue, Q3 FY2026
–
EPS, Q3 FY2026
-$0.17
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Black Diamond Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 15, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 10, 2026before the open––-$0.17Release
Q2 FY2026ended Jun 30, 2026Aug 5, 2026during market hours––-$0.17Release
Q1 FY2026ended Mar 31, 2026May 7, 2026before the open––-$0.16Release
Q4 FY2025ended Dec 31, 2025Mar 16, 2026during market hours––-$0.27Release
Q3 FY2025ended Sep 30, 2025Nov 6, 2025before the open–––Release
Q2 FY2025ended Jun 30, 2025Aug 7, 2025before the open––-$0.19Release
Q1 FY2025ended Mar 31, 2025May 12, 2025during market hours–––Release
Q4 FY2024ended Dec 31, 2024Mar 6, 2025during market hours–––Release
Q3 FY2024ended Sep 30, 2024Nov 5, 2024before the open–––Release
Q2 FY2024ended Jun 30, 2024Aug 6, 2024before the open––-$0.36Release
Q1 FY2024ended Mar 31, 2024May 9, 2024before the open––-$0.35Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Black Diamond Therapeutics has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Black Diamond Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Black Diamond Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Black Diamond Therapeutics Announces Positive Updated Silevertinib Phase 2 Results, FDA Feedback Supporting a Clear Path to Potential Registration in 1L EGFR-NCM NSCLC, and Provides Corporate Update
    Results
  2. Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
    Results
  3. Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations
    Update
  4. Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
    Results
  5. Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
    Results
  6. Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM
    Results
  7. Quarterly results release
    Results
  8. Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
    Results
  9. Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
    Results
  10. Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
    Results
  11. Servier and Black Diamond Therapeutics
    Update
  12. Thank You Partnership: [email protected] Investors: [email protected] Media: [email protected]
    Update
  13. Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
    Results
  14. Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
    Results
  15. Black Diamond Therapeutics Announces Restructuring
    Update

See a number that looks wrong?